NHWA(SZ:002262) Xin Lang Cai Jing·2025-07-30 01:23Core Insights - Enhua Pharmaceutical (002262.SZ) reported a total revenue of 3.01 billion yuan for the first half of 2025, marking an increase of 247 million yuan compared to the same period last year, achieving a continuous growth for five years with a year-on-year increase of 8.93% [1] - The net profit attributable to shareholders reached 700 million yuan, an increase of 71.57 million yuan from the same period last year, also achieving five consecutive years of growth with a year-on-year increase of 11.38% [1] - The company reported a net cash inflow from operating activities of 495 million yuan [1] Financial Ratios - The latest debt-to-asset ratio stands at 13.01%, a decrease of 1.38 percentage points from the previous quarter [1] - The latest gross profit margin is 75.24%, an increase of 0.55 percentage points from the previous quarter, achieving two consecutive quarters of growth and a year-on-year increase of 2.74 percentage points [1] - The latest return on equity (ROE) is 9.13% [1] Earnings Per Share - The diluted earnings per share (EPS) is 0.69 yuan, an increase of 0.07 yuan compared to the same period last year, achieving five consecutive years of growth with a year-on-year increase of 11.29% [1] Asset Management - The latest total asset turnover ratio is 0.35 times [1] - The latest inventory turnover ratio is 1.06 times [1] Shareholder Structure - The number of shareholders is 43,600, with the top ten shareholders holding a total of 550 million shares, accounting for 54.16% of the total share capital [1] - The top shareholders include: 1. Xuzhou Enhua Investment Co., Ltd. - 31.5% 2. Sun Pengsheng - 4.85% 3. Yi Zengliang - 3.93% 4. Fu Ce - 3.93% 5. Yang Ziliang - 3.65% 6. Zhang Xu - 2.15% 7. Ma Wusheng - 1.22% 8. China Life Insurance Co., Ltd. - 1.11% 9. Agricultural Bank of China - 0.89% 10. National Social Security Fund - 0.84% [1]